AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04406948 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Blood and urine collection
Description: safety blood tests - hematology\\blood count and biochemistry standard blood tests urinalysis - urine test analysis
Study NCT05707468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT combined with abiraterone
Description: The patients will receive long-term ADT combined with abiraterone.
Study NCT05707468 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant hormone and RT
Description: The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.
Study NCT06185257 — intervention group
Intervention type: DEVICE
Intervention: EEG
Description: Methodology Subjects selected are divided into 3 groups A. Patient with chronic kidney disease under dialysis B. Patients with nephrotic syndrome~* Patients in remission~* Patients relapse C. Normal control group~Detailed history including age, sex , residence ,complain, renal symptoms will be taken.~Detailed examination, lab investigations, and treatment will be recorded~Imaging ( EEG) , results of the three groups will be assessed and compared and lab investigation ( lipid profile of all patients) will be measured
Study NCT05807243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention for healthy weight loss
Description: Balanced and varied dietary plan adjusted to each participant's needs, with an approximate reduction of 500 Kcal from their total metabolic expenditure. The diet will be followed by the subjects during the 4 weeks of the study.
Study NCT05404477 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TransAeris System
Description: The TransAeris System includes four TransLoc® intramuscular diaphragm electrodes, the TransAeris external stimulator, and the FrictionLoc® connectors which provide the interface between the TransLoc electrodes and the TransAeris stimulator.
Study NCT06684249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Block Injections
Description: This intervention involves the administration of supratrochlear and greater occipital nerve block injections. The injections consist of a mixture of local anesthetics and corticosteroids, designed to reduce the frequency and severity of migraine episodes. The procedure will be repeated every 12 weeks for a total duration of 6 months to assess the long-term efficacy and safety in managing chronic migraine.
Study NCT06684249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin A
Description: Participants in this arm will receive Botulinum toxin A injections as per the PREEMPT protocol tailored for chronic migraine treatment. The treatment involves multiple injections around the head and neck regions, administered every 12 weeks over a 6-month period. This standard approach aims to reduce migraine frequency through neuromodulation of pain pathways.
Study NCT06683391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment
Description: The intervention in the REMODAL trial involves administering specific amounts of oral carbohydrates (CHO) at different glucose thresholds to evaluate the effectiveness of proactive versus reactive hypoglycemia management strategies in adults with Type 1 diabetes using continuous glucose monitoring (CGM). Participants will undergo three distinct interventions, each designed to test a different amount and timing of CHO intake.
Study NCT06683391 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment
Description: The intervention in the REMODAL trial involves administering specific amounts of oral carbohydrates (CHO) at different glucose thresholds to evaluate the effectiveness of proactive versus reactive hypoglycemia management strategies in adults with Type 1 diabetes using continuous glucose monitoring (CGM). Participants will undergo three distinct interventions, each designed to test a different amount and timing of CHO intake.
Study NCT05010564 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy
Description: Three dose levels will be evaluated with the opportunity to dose de-escalate (dose level -1) for toxicity.~DL-1: 3x10\^6 cells/m2~DL1: 1×10\^7 cells/m2~DL2: 3×10\^7 cells/m2~DL3: 1×10\^8 cells/m2~Lymphodepletion chemotherapy consisting of Fludarabine 30 mg/m2 IV once daily x 4 doses; and Cyclophosphamide 500mg/m2 IV once daily x 2 doses (starting with the first dose of fludarabine)must be completed greater than or equal to 48 hours prior to infusion of CAR-T cells.~The protocol will allow for up to three additional infusions of the CAR-T product for subjects who meet criteria for retreatment.
Study NCT06683300 — intervention group
Intervention type: DRUG
Intervention: DAPT for 3 months after vertebral artery stenting
Description: After implantation of a drug-eluting stent in the vertebral artery, dual antiplatelet therapy (DAPT) were administered for 3 months. The types of antiplatelet medications are not limited, with the standard regimen consisting of aspirin 100 mg once daily combined with either clopidogrel 75 mg once daily or ticagrelor 90 mg twice daily. Additional antiplatelet agents such as indobufen may also be considered acceptable.
Study NCT06685432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: The effect of motivational interviewing techniques was examined in addition to diet treatment. The effect of motivational interviewing techniques on anthropometric measurements before and after the study was evaluated. The participants' indecisiveness was investigated and a self-directed change conversation was presented. Behavior change strategies including determining positive and negative aspects, using importance and confidence scales, and setting the agenda were applied by the researcher.~In the interviews that included motivational interviewing techniques:~1. A participant-centered interview was conducted by collaborating with the participant.~2. The researcher was impartial and did not assume the role of an expert.~3. At the beginning of the interview, an evaluation of what was discussed in the previous week was made.~4. First of all, an attempt was made to determine the agenda according to the topic the participant wanted to discuss.~5. The importance scale was used (1-10).
Study NCT05664152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1111
Description: BARYCELA inj.
Study NCT02933554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embospheres Microspheres
Description: Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
Study NCT06507046 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Mechanical or Personalized alignment
Study NCT06507046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee replacement
Description: Mechanical or Personalized alignment
Study NCT06227975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BMS-986368
Description: Specified dose on specified days
Study NCT05836350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4.8 g/m^2/day NaPB
Description: 12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
Study NCT05836350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4.8 g/m^2/day placebo
Description: 12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
Study NCT04806984 — intervention group
Intervention type: OTHER
Intervention: Participant outreach
Description: Participants in the experimental arms will receive a call center phone call or MyChart message to remind them to schedule their appointments.
Study NCT06243705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Pet
Description: The robot-pet makes sounds like a real cat and responds to touch and petting
Study NCT06243705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Glasses
Description: VR glasses allow you to see videos and films projected on the screen more realistic. With its filtering feature, it combines two different images in the brain and provides the perception of depth in the image and creates a 3D space environment
Study NCT05838807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Ultrasound
Description: Participants in this group will receive thermal ultrasound treatment using a gel-coupled ultrasound probe that delivers continuous ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 5 minutes per session, three times per week, for four weeks. The intensity of the ultrasound wave will be set at 1.0 W/cm2 applied for 5 minutes. The treatment will be administered three times per week, for four weeks.
Study NCT05838807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Ultrasound
Description: Participants in this group will receive pulsed ultrasound treatment using a gel-coupled ultrasound probe that delivers pulsed ultrasound waves at a frequency of 1 Mega Hertz. The ultrasound probe will be moved continuously over the affected wrist and hand region for 15 minutes with 25% duty cycle and intensity of 1.0 W/cm2.The treatment will be administered three times per week, for four weeks.
Study NCT05838807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Ultrasound
Description: Participants in this group will receive a combination of thermal and pulsed ultrasound treatments. The thermal ultrasound treatment will be administered first for 5 minutes, followed by the pulsed ultrasound treatment for another 15 minutes. The same parameters as described above will be used for each treatment modality. The combination treatment will be administered three times per week, for four weeks.
Study NCT05838807 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ultrasound
Description: Participants in this group will receive a placebo ultrasound treatment that looks and feels identical to the active ultrasound treatments, but does not deliver any therapeutic effects. The placebo treatment will be administered using the same gel-coupled ultrasound probe for 15 minutes per session, three times per week, for four weeks, with the intensity set at 0 W/cm² and the temperature maintained at room temperature.
Study NCT05589870 — intervention group
Intervention type: OTHER
Intervention: Multi-drug analysis of polypharmacy treatment
Description: Multi-drug analysis to assess and provide insights for lowering the risk of ADRs and increasing the benefit of polypharmacy treatment
Study NCT05892315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeated subgingival instrumentation
Description: Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
Study NCT05892315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supragingival scaling
Description: Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.
Study NCT05651854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pranayama breathing
Description: Bhramari and sheetali pranayama breathing
Study NCT05794776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BurstDR stimulation
Description: BurstDR spinal cord stimulation
Study NCT04675450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
Study NCT04675450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NBP Softgel Capsules
Description: Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
Study NCT06319417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HT treatment
Description: Total consumption of 60 mg/day of HT
Study NCT06319417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Consumption of placebo treatment of 4 caramels/day
Study NCT05794776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tonic stimulation
Description: Tonic spinal cord stimulation
Study NCT05794776 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: No stimulation
Description: Stimulator is switched off
Study NCT05979753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EFFECTS OF HIGH INTENSITY INTERVAL TRAINING IN SPRINTERS
Description: EFFECTS OF HIGH INTENSITY INTERVAL TRAINING ON SPEED AND EXPLOSIVE STRENGTH IN SPRINTER
Study NCT05649111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Difluprednate Eye Drops
Description: post-operative cataract surgery medication regimen. but different dosages between the 2 groups.
Study NCT05672147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD33 CAR T-cells
Description: Given IV
Study NCT05672147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphodepletion Therapy
Description: Undergo lymphodepletion
Study NCT04666701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escócia association
Description: Escócia association tablet
Study NCT04666701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Ketorolac
Description: Placebo Ketorolac tablet
Study NCT04666701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Ketorolac
Description: Placebo Ketorolac tablet
Study NCT04666701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Scopolamine
Description: Placebo Scopolamine dragee
Study NCT05763966 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational study where participants are followed over time
Study NCT04666701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Scopolamine
Description: Placebo Scopolamine dragee
Study NCT05016154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Group CBT intervention
Description: Group of participants complete 10 weeks of Online Group CBT intervention
Study NCT05016154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SilverCloud guided
Description: Group of participants make use of the SilverCloud guided app
Study NCT05016154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SilverCloud Unguided
Description: Group of participants make use of the SilverCloud Unguided app
Study NCT05016154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood Flow
Description: Group of participants make use of the Mood Flow app
Study NCT06472401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Learning Support System
Description: Students will receive simulation preparation with an Integrated Learning Support System consisting of:~* Educational technology in comic book format~* Virtual monitoring system with tutors~* Psychological follow-up~* Music listening and relaxation session
Study NCT06472401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Learning Model
Description: Students will receive standard simulation preparation consisting of:~- Expository and dialogued theoretical class.
Study NCT05085119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stepwise modifications of FiO2
Description: FiO2 will be increased stepwise from 30 to 100% (40, 60 and 80%), and then decreased with the same FiO2 reverse steps.
Study NCT04666701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: Ketorolac tablet
Study NCT04666701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: Scopolamine dragee
Study NCT04666701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Escócia association
Description: Placebo Escócia association tablet
Study NCT05650645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: incobotulinum toxin A
Description: The study intervention is a syringe of 50 units of incobotulinum toxin A total, with 25 units per side, a total of 6 injection sites incobotulinum toxin A diluted into 1 ml of normal saline, injected in equal amounts into the anterior, superior, and posterior auricular muscles using anatomical landmarks. This will be approximately 0.16 mL (8-9 units) of the combined solution per injection site.
Study NCT05650645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Saline
Description: Placebo injections will be preservative free normal saline. Injections will be administered similar to the drug injections.
Study NCT04580134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clozapine
Description: Biotype 1 and Biotype 2
Study NCT04580134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clozapine
Description: Biotype 1 and Biotype 2
Study NCT04580134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone
Description: Biotype 1 and Biotype 2
Study NCT05778968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low etco2
Description: Etco2 levels will be adjusted at levels ranging between 25 mm Hg and 30 mm Hg
Study NCT04620291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
Study NCT05778968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: normal etco2
Description: Etco2 levels will be adjusted at levels ranging between 31 mm Hg and 40 mm Hg
Study NCT05778968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high etco2
Description: Etco2 levels will be adjusted at levels ranging between 41 mm Hg and 45 mm Hg
Study NCT04431193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin infused to maintain serum concentrations of 4, 16, 64, and 256 picogram/millilitre
Study NCT05738187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local cryotherapy treatment
Description: cryotherapy
Study NCT05039372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRAINING AND CONSULTANCY
Description: TRAINING AND CONSULTANCY
Study NCT05408806 — intervention group
Intervention type: OTHER
Intervention: Exercise Interventions
Description: Rehabilitation methods and exercise practices to improve postural control in children with cerebral palsy. In addition to neurodevelopmental treatment, one group is treated with virtual reality games and the other group is treated with a hippotherapy simulator.
Study NCT05883072 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exploring AI-Chatbot
Description: All participants will be provided access to AI-Chatbot and will be asked to enquire their daily life problems related to diabetes. They will also be asked to review the replies of the Chatbot after their interaction.
Study NCT05347979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Dabigatran will be administered orally as a 75 mg capsule on Day 1 and Day 12.
Study NCT05347979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant will be administered orally as 4 X 100 mg capsules (400 mg) on Days 3 through 13.
Study NCT06276270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucopad HA
Description: The product is a Class III Medical Device incorporating a medicinal substance (antiseptics-octenidine) within the composition made of sodium hyaluronate polysacharide stabilised by calcium chloride. Device is administered directly onto the area affected by mucositis.
Study NCT05639790 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes + Health Counselling
Description: Ad libitum use of electronic cigarettes for 1 month
Study NCT05639790 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Health Counselling
Description: Health Counselling from a licensed mental health counselor
Study NCT05639790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Counselling
Description: Health Counselling from a licensed mental health counselor